Medidata
As the industry is coming to know, risk-based monitoring can significantly reduce study monitoring costs through the promise of reducing on-site visits. Over the past few years, there has been a downward trend in the number of visit days per year, per site across the clinical trial landscape, as supported by data pulled from the Medidata InsightsTM metrics warehouse (Figure 1).
Based on this trend, some might assume there would also be a similar reduction in the query open rate of site monitors coupled with a corresponding uptick in the number of data manager queries—indicating possible “compensation” for mistakes/inconsistencies not captured by monitors.
However, based on the analysis depicted in Figure 1, the number of site monitor and data manager queries has remained relatively flat since 2010. Conversely, there was an increase in the rate of auto queries—those generated programmatically by the electronic data capture (EDC) system in response to electronic case report form (eCRF) data entries that violate rules/boundary conditions. Auto queries are generated at the time of data entry and flag many of the data errors that would otherwise be manually detected by site monitors or data managers. Since the per-query cost for auto queries is significantly lower than that for manual queries, using edit check/auto query technology delivers a more attractive return on investment (ROI) than manual queries. Further, the analysis revealed a 16% increase in the frequency of auto queries over the three-year period that inversely corresponds to a 28% decrease in the site visit rate.
Based on this analysis of the data, we conclude that the higher rate of auto queries is not specifically related to the decrease in on-site monitoring, but rather a result of increased adoption of the edit checking technology inherent in most EDC systems. This is a positive sign that the industry is maturing in its use of EDC and realizing the tremendous value this capability offers toward ensuring data quality. The results may also indicate that site monitors are becoming more efficient since their query rates remain level for both on- and off-site queries, even though they’re spending fewer days at sites year after year. So even though sites may not be seeing their site monitors as frequently, they can rest assured knowing their query rate remains the same!
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.